31 Reasons To Reject The Jab

way 2 go

Well-known member
Long Term Follow-Up After Administration of Human Gene Therapy
Products Guidance for Industry


1. The integration activity of the GT product: The biological activity of retroviral vectors4 ( e.g., vectors derived from gammaretrovirus, lentivirus, foamy virus etc.) and transposon elements is imparted by an integration event in the genome. In general, such integration is not directed to specific sites in the human genome, and this raises the potential for disruption of critical host (human) genes at the site of integration, or activation of proto-oncogenes near the integration site(s) and, thereby, the risk for malignancies.

2. Genome editing activity: Genome editing-based GT products impart their biological activity through site-specific changes in the human genome, but may also have off-target effects on the genome (Ref. 2). Similar to integrating vectors, genome editing may produce undesirable changes in the genome ( whether ex vivo or in vivo), with the risk of malignancies, impairment of gene function, etc.

3. Prolonged expression: A GT product where the transgene (therapeutic gene) encodes growth factors, such as vascular endothelial growth factor (VEGF) or proteins associated with cell division such as p53, may raise the potential for unregulated cell growth and malignancies due to prolonged exposure to the therapeutic protein. Similarly, transgenes encoding immune recognition factors may introduce the risk for autoimmune-like reactions ( to self-antigens) upon prolonged exposure. For GT products that carry transcriptional regulatory elements (e.g., microRNA) or immune-modulatory proteins ( e.g., c ytokines) there is also the risk of unknown pleotropic effects, including altered expression of host (human) genes that could result in unpredictable and undesirable outcomes.

4. Latency: When the GT product has the potential for latency, such as a herpes virus, there is the potential for reactivation from latency and the risk of delayed adverse events related to a symptomatic infection.

5. Establishment of persistent infections: GT products that are replication competent viruses and bacteria, such as listeria-based bacterial vectors, have the potential to establish persistent infections in immunocompromised patients leading to the risk of developing a delayed but serious infection. .


 

way 2 go

Well-known member
Long Term Follow-Up After Administration of Human Gene Therapy
Products Guidance for Industry


1. The integration activity of the GT product: The biological activity of retroviral vectors4 ( e.g., vectors derived from gammaretrovirus, lentivirus, foamy virus etc.) and transposon elements is imparted by an integration event in the genome. In general, such integration is not directed to specific sites in the human genome, and this raises the potential for disruption of critical host (human) genes at the site of integration, or activation of proto-oncogenes near the integration site(s) and, thereby, the risk for malignancies.

2. Genome editing activity: Genome editing-based GT products impart their biological activity through site-specific changes in the human genome, but may also have off-target effects on the genome (Ref. 2). Similar to integrating vectors, genome editing may produce undesirable changes in the genome ( whether ex vivo or in vivo), with the risk of malignancies, impairment of gene function, etc.

3. Prolonged expression: A GT product where the transgene (therapeutic gene) encodes growth factors, such as vascular endothelial growth factor (VEGF) or proteins associated with cell division such as p53, may raise the potential for unregulated cell growth and malignancies due to prolonged exposure to the therapeutic protein. Similarly, transgenes encoding immune recognition factors may introduce the risk for autoimmune-like reactions ( to self-antigens) upon prolonged exposure. For GT products that carry transcriptional regulatory elements (e.g., microRNA) or immune-modulatory proteins ( e.g., c ytokines) there is also the risk of unknown pleotropic effects, including altered expression of host (human) genes that could result in unpredictable and undesirable outcomes.

4. Latency: When the GT product has the potential for latency, such as a herpes virus, there is the potential for reactivation from latency and the risk of delayed adverse events related to a symptomatic infection.

5. Establishment of persistent infections: GT products that are replication competent viruses and bacteria, such as listeria-based bacterial vectors, have the potential to establish persistent infections in immunocompromised patients leading to the risk of developing a delayed but serious infection. .


Captutufvcybiubone.JPG

"along with other factors like genetics "
they meant genetically modified

got the shot , congratulations you are now GMO
 

way 2 go

Well-known member

if covid vaccines work then why haven't they worked?​

the highest vaxxed states in the US did not see reductions in hospitalizations. but they did see a rise in all cause deaths.​

we see a worrying pattern in much of northern new england. jan-jun 2021 was the meat of the vaccines campaign there. overall vaxx rates were very high, but just a couple months post getting over 50-60% we see unseasonable early and higher rates of hospitalization in vermont. we also see a surge in excess mortality that remains sustained.

https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2F1881c075-cb07-446e-ba67-0b0ffdc2906c_1548x1435.png


thinking that reducing walking deaths by 4 was a great outcome because you missed the fact that you added 9 new driving deaths.


 

ok doser

lifeguard at the cement pond
Long Term Follow-Up After Administration of Human Gene Therapy
Products Guidance for Industry


1. The integration activity of the GT product: The biological activity of retroviral vectors4 ( e.g., vectors derived from gammaretrovirus, lentivirus, foamy virus etc.) and transposon elements is imparted by an integration event in the genome. In general, such integration is not directed to specific sites in the human genome, and this raises the potential for disruption of critical host (human) genes at the site of integration, or activation of proto-oncogenes near the integration site(s) and, thereby, the risk for malignancies.

2. Genome editing activity: Genome editing-based GT products impart their biological activity through site-specific changes in the human genome, but may also have off-target effects on the genome (Ref. 2). Similar to integrating vectors, genome editing may produce undesirable changes in the genome ( whether ex vivo or in vivo), with the risk of malignancies, impairment of gene function, etc.

3. Prolonged expression: A GT product where the transgene (therapeutic gene) encodes growth factors, such as vascular endothelial growth factor (VEGF) or proteins associated with cell division such as p53, may raise the potential for unregulated cell growth and malignancies due to prolonged exposure to the therapeutic protein. Similarly, transgenes encoding immune recognition factors may introduce the risk for autoimmune-like reactions ( to self-antigens) upon prolonged exposure. For GT products that carry transcriptional regulatory elements (e.g., microRNA) or immune-modulatory proteins ( e.g., c ytokines) there is also the risk of unknown pleotropic effects, including altered expression of host (human) genes that could result in unpredictable and undesirable outcomes.

4. Latency: When the GT product has the potential for latency, such as a herpes virus, there is the potential for reactivation from latency and the risk of delayed adverse events related to a symptomatic infection.

5. Establishment of persistent infections: GT products that are replication competent viruses and bacteria, such as listeria-based bacterial vectors, have the potential to establish persistent infections in immunocompromised patients leading to the risk of developing a delayed but serious infection. .


I was going to dig this one out later!
 

Idolater

"Matthew 16:18-19" Dispensationalist (Catholic) χρ
It's really remarkable how the quote-unquote "vaccines" work. They 'trick' the body into making the 'real' vaccine, is how these things work. The real vaccine is the spike proteins. You can't get enough spike proteins 'injected'. You'd need gallons of the stuff. So instead of that, fortunately, we have the tech to 'trick' the body into making the real vaccine for us. So instead of gallons getting injected into you, to get enough spike protein into you, in order to work as a real vaccine, to provoke the immune system in a predictable manner through the introduction of just the right kind of foreign material; and it's just milligrams.

Hopefully there are no chronic effects, everybody's fingers are crossed on this one, whether they are permitted through partisan expediency to admit it or not, every knowledgeable thinking person knows there remains this looming "known" unknown (aside from the "unknown unknowns" tip of the cap to Mr. Donald Rumsfeld) of chronic effects of this gene therapy drug.

We'll see. We all really hope that we didn't save millions just to lose billions in the future. We're just making the best judgment of the thing with the information we have (evidence) and logic. The effect of the drug wears off, this is a very good sign that the drug completely metabolizes and leaves no trace, or at least that the effect long term will be the same as if it does completely metabolize leaving no (ill) trace.

ITNOTFAOTSAOTHSA. (Prayer)
 

Idolater

"Matthew 16:18-19" Dispensationalist (Catholic) χρ
It's really remarkable how the quote-unquote "vaccines" work. They 'trick' the body into making the 'real' vaccine, is how these things work. The real vaccine is the spike proteins. You can't get enough spike proteins 'injected'. You'd need gallons of the stuff. So instead of that, fortunately, we have the tech to 'trick' the body into making the real vaccine for us. So instead of gallons getting injected into you, to get enough spike protein into you, in order to work as a real vaccine, to provoke the immune system in a predictable manner through the introduction of just the right kind of foreign material; and it's just milligrams.

Hopefully there are no chronic effects, everybody's fingers are crossed on this one, whether they are permitted through partisan expediency to admit it or not, every knowledgeable thinking person knows there remains this looming "known" unknown (aside from the "unknown unknowns" tip of the cap to Mr. Donald Rumsfeld) of chronic effects of this gene therapy drug.

We'll see. We all really hope that we didn't save millions just to lose billions in the future. We're just making the best judgment of the thing with the information we have (evidence) and logic. The effect of the drug wears off, this is a very good sign that the drug completely metabolizes and leaves no trace, or at least that the effect long term will be the same as if it does completely metabolize leaving no (ill) trace.

ITNOTFAOTSAOTHSA. (Prayer)
Bump.
 
Top